STRIDE - STimulating Immune Response In aDvanced brEast Cancer
- Conditions
- Breast Cancer
- Interventions
- Biological: Placebo of tecemotide (L-BLP25) and Hormonal TreatmentBiological: Tecemotide (L-BLP25) and Hormonal Treatment
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 16
- Registration Number
- NCT00925548
- Locations
- 🇿🇦
Research Site, Johannesburg, South Africa
Atacicept in Multiple Sclerosis Extension Study, Phase II
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 74
- Registration Number
- NCT00853762
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
- Conditions
- Glioblastoma
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 265
- Registration Number
- NCT00813943
- Locations
- 🇺🇸
Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
🇩🇪Please Contact the Merck KGaA Communication Center Located in, Darmstadt, Germany
12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 106
- Registration Number
- NCT00735007
- Locations
- 🇺🇸
US Local Medical Information, Rockland, Massachusetts, United States
🇨🇦Canada, Local Medical Information, Ontario, British Columbia, Quebec, Canada
🇩🇪Germany, Local Medical Information, Hamburg, Ulm, Berlin, Erbach, Germany
Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 21
- Registration Number
- NCT00719199
- Locations
- 🇺🇸
Georgetown University Lombardi Cancer Center, Washington, DC, District of Columbia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 599
- Registration Number
- NCT00702065
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
🇦🇷Reseach site, Buenos Aires, Argentina
🇪🇸Reseach Site, Malaga, Spain
Oocyte Cryopreservation Registry (HOPE Registry)
- Conditions
- Oocyte Cryopreservation
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 204
- Registration Number
- NCT00699400
- Locations
- 🇺🇸
Research Site, bryn Mawr, Pennsylvania, United States
🇺🇸US Local Med Info Office, Rockland, Massachusetts, United States
🇺🇸Research Stie, New York, New York, United States
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 545
- Registration Number
- NCT00689221
- Locations
- 🇺🇸
Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
🇩🇪Please Contact the Merck KGaA Communication Center Located in, Darmstadt, Germany
Easypod United States User Trial
- Conditions
- Growth Hormone Deficiency
- Interventions
- Device: easypod
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 42
- Registration Number
- NCT00689260
- Locations
- 🇺🇸
US Medical Information, Rockland, Massachusetts, United States
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 255
- Registration Number
- NCT00642902
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom